Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced breast cancer patients in early trial

NCT ID NCT06167694

Recruiting now Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 08, 2026 · Updated 18 times

Summary

This study tests a new combination of two drugs (HRS-8080 and dalpiciclib) for people with a common type of advanced breast cancer (ER-positive, HER2-negative) that cannot be removed by surgery or has spread. About 146 women aged 18-75 will take part to find the best dose and see if the combo shrinks tumors. The goal is to control the cancer, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital Fifth Medical Center

    RECRUITING

    Beijing, Beijing Municipality, 100000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sun Yat-sen University Cancer Center (SYSUCC)

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

UNRESECTABLE OR METASTATIC BREAST CANCER